AIM-102

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H27N3O6
Molecular Weight	357.4021
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@H](CC1CCCCC1)C(=O)N[C@H](CCC(O)=O)C(=O)NCC(O)=O

InChI

InChIKey=CNDMSQXUUIBFPE-VXGBXAGGSA-N

InChI=1S/C16H27N3O6/c17-11(8-10-4-2-1-3-5-10)15(24)19-12(6-7-13(20)21)16(25)18-9-14(22)23/h10-12H,1-9,17H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)/t11-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H27N3O6
Molecular Weight	357.4021
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:29:04 GMT 2023` Edited by `admin` on `Sat Dec 16 11:29:04 GMT 2023`
Record UNII	3JX85UOO24
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AIM-102

Common Name

English

D-CYCLOHEXYLALANINE-D-GLUTAMIC-GLYCINE TRIPEPTIDE

Common Name

English

(4R)-4-(((2R)-2-AMINO-3-CYCLOHEXYL-PROPANOYL)AMINO)-5-(CARBOXYMETHYLAMINO)-5-OXO-PENTANOIC ACID

Systematic Name

English

GLYCINE, 3-CYCLOHEXYL-D-ALANYL-D-.ALPHA.-GLUTAMYL-

Systematic Name

English

Code System Code Type Description

PUBCHEM

10126114

Created by admin on Sat Dec 16 11:29:04 GMT 2023 , Edited by admin on Sat Dec 16 11:29:04 GMT 2023

PRIMARY

EPA CompTox

DTXSID20435890

Created by admin on Sat Dec 16 11:29:04 GMT 2023 , Edited by admin on Sat Dec 16 11:29:04 GMT 2023

PRIMARY

CAS

551936-17-5

Created by admin on Sat Dec 16 11:29:04 GMT 2023 , Edited by admin on Sat Dec 16 11:29:04 GMT 2023

PRIMARY

FDA UNII

3JX85UOO24

Created by admin on Sat Dec 16 11:29:04 GMT 2023 , Edited by admin on Sat Dec 16 11:29:04 GMT 2023

PRIMARY

Related Record Type Details


					3JX85UOO24

AIM-102

ACTIVE MOIETY

Comments:

Originator: AIM Therapeutics; Class: Anti-inflammatory, Anti-asthmatic, Peptide; Mechanism of Action: Immunomodulator; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Available For Licensing: Yes; Highest Development Phases: Discontinued for Asthma, Chronic obstructive pulmonary disease; Most Recent Events: 01 Mar 2013 AIM Therapeutics completes phase II trial in Asthma (NCT01501942), 25 Oct 2012 AIM 102 is available for licensing after the completion of phase IIa trials. http://www.aimtherapeutics.com, 22 Oct 2012 Phase-II clinical trials in Asthma in Canada (PO)